Drug industry steps up for credentialing group

Share this article:
The National Commission for the Certification of CME Professionals' voluntary certification program will not be out until fall 2007. That has not kept AstraZeneca and Merck, as well as several medical education entities from becoming “charter donors.” To earn the credential, candidates will have to meet specific criteria based on evidence of professional performance,
experience and completion of self-assessment, according to information on NC-CME.org.

Judy Ribble, PhD, NC-CME president, said she hopes small donations help the group attract a large foundation grant.

Maureen Doyle-Scharff, director of professional alliances, Ross, said, credentialing “would be a very positive step in the right direction from an industry perspective,” as a way to help ensure proposal competency.

Some medical societies agree, as their CME staffs need an increasingly broad skill set to collaborate on maintenance of certification.

Not everyone fully endorses NC-CME, and questions linger, such as who will pay for the
credential and test questions, who should take the exam and what's an apt re-certification plan.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...